Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

Simona Di Giambenedetto, Giuseppe Lapadula, Silvia Costarelli, Liliane Chatenoud, Francesco Castelli, Noemi Astuti, Eugenia Quiros-Roldan, Laura Sighinolfi, Nicoletta Ladisa, Massimo Di Pietro, Alessia Zoncada, Elisa Di Filippo, Andrea Gori, Paola Nasta, Carlo Torti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)

Abstract

The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.
Lingua originaleEnglish
pagine (da-a)312-318
Numero di pagine7
RivistaJournal of Acquired Immune Deficiency Syndromes
Volume69
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Adult
  • Anti-HIV Agents
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • HIV Infections
  • Hepatitis B
  • Hepatitis C
  • Humans
  • Italy
  • Liver
  • Male
  • Middle Aged
  • Protease Inhibitors
  • Risk Factors
  • Ritonavir

Fingerprint Entra nei temi di ricerca di 'Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients'. Insieme formano una fingerprint unica.

Cita questo